PTPRC and neoplasm: Using their gating strategy, we still saw a significant decrease in tumour macrophages (CD45+CD11b+F480+Ly6C−, 0.6 FC, p = 0.0021) and increase in splenic macrophages (3.1 FC, p < 0.0001, Figure S5A,C).